Furthermore, in a syngeneic breast cancer mouse model, co-treatment with Trastuzumab and anti-CD47 mAbs improved tumour control and was associated with macrophage pro-inflammatory polarisation and cytotoxic gene expression in CD8+ T cells [107]. The gene discussed is CD47; the disease is neoplasm.